Sign up for free insights newsletter
LI

LivaNova PLC

LIVNUnited States

Need professional-grade analysis? Visit stockanalysis.com

$62.40
+0.34%
End of day
Market Cap

$3.46B

P/E Ratio

54.70

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-2.62-1.81-0.181.712.520.84
Calmar-29.45-3.79-0.242.133.19-0.89
Sharpe-1.96-1.33-0.121.031.290.37
Omega0.340.581.001.221.291.06
Martin-42.44-7.63-0.859.068.501.23
Ulcer0.708.785.024.156.635.54

LivaNova PLC (LIVN) Price Performance

LivaNova PLC (LIVN) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at $62.40, up 0.34% from the previous close.

Over the past year, LIVN has traded between a low of $33.85 and a high of $71.00. The stock has gained 56.4% over this period. It is currently 12.1% below its 52-week high.

LivaNova PLC has a market capitalization of $3.46B, with a price-to-earnings ratio of 54.70.

About LivaNova PLC

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$1.39B
EBITDA
$257.66M
Profit Margin
-17.47%
EPS (TTM)
-4.45
Book Value
21.96

Technical Indicators

52 Week High
$71.92
52 Week Low
$32.48
50 Day MA
$64.96
200 Day MA
$55.52
Beta
0.95

Valuation

Trailing P/E
54.70
Forward P/E
13.82
Price/Sales
2.49
Price/Book
2.88
Enterprise Value
$3.26B